Medicilon Inc.’s Post

Thrilled to share that Medicilon Inc. is at the forefront of cancer research with our Patient-Derived Xenograft Organoids (#PDXOs). These 3D models replicate tumor features with exceptional accuracy, bridging the gap between in vivo and in vitro studies. We've developed nine PDXO models for various cancers, ensuring high quality and reliability. If you're interested in learning more, feel free to reach out to me! #PDXO #organoid #models

Join us on September 17, 2024, from 10-11 AM EST for an insightful webinar with Dr. Andrew Satterlee, as he discusses the cutting-edge advancements in functional drug screening of patient tumor tissues. Learn how his innovative ex vivo platform is transforming cancer treatment by accelerating pre-clinical drug testing and providing actionable insights for personalized medicine. Save the date and register for free: https://lnkd.in/eV6R5G57 Don’t miss this opportunity to explore how these technologies are shaping the future of oncology research! #CancerResearch #PrecisionMedicine #PrecisionaryInstruments #compresstome #microtomes #vibratingmicrotomes #vibratomes #tissuesectioning #precisioncuttissuesslices #tissueslicing #laboratoryequipment #labsolutions

NEW from #ASCO2024 | Evaluating JZP898, an IFN-α and #pembrolizumab in advanced #solidtumors 🎥 🇺🇸 Meredith McKean, MD, MPH, Sarah Cannon Research Institute, shares findings from a Phase I, first-in-human study (NCT06108050) of JZP898, a conditionally activated prodrug of interferon alpha (IFN-α), alone or combined with #pembrolizumab in patients with advanced or #metastatic #solidtumors 🌟 The study aims to determine the maximum tolerated dose, safety, tolerability, #pharmacokinetics, and preliminary #antitumor activity 🌟 The combination is designed to enhance antitumor effects while minimizing systemic toxicity 🌟 Primary endpoints include dose-limiting toxicities and objective response rate, with secondary endpoints covering pharmacokinetics and overall survival Learn more 👉 https://lnkd.in/gzjRxJY7 #VJOncology #Oncologynews

In a recent review article, Oldan and colleagues highlight promising novel oncology radiotracers including Zirconium-89 (89Zr)-girentuximab that target carbonic anhydrase IX (CAIX). Authors note that fluorodeoxyglucose (which is excreted via the kidneys and urinary tract) is insensitive and not suitable for renal cell carcinoma (RCC) imaging, and sestamibi is not able to detect metastasis; thus, a high unmet need exists for a radiotracer that can detect and characterize primary RCC and metastatic lesions. The article features images from two cases in Telix’s Phase III ZIRCON trial that demonstrate the clinical utility of 89Zr-girentuximab PET for detection and characterization of clear cell RCC. Authors also note that CAIX-targeting agents may have additional utility for imaging hypoxic tumors, which Telix is exploring along with therapeutic potential in a prospective, open label Phase II “basket” trial (“STARBURST”). Article preview: https://lnkd.in/gRTPkpjW

How can we integrate molecular profiling into clinical care to drive treatment decisions for patients with HER2+ advanced solid tumors? Join us at #ESMOASIA24 on 12/8 for a LIVE event on effective strategies in HER2+ solid tumor care: https://lnkd.in/esRqJD8j #CME #Oncology

BICR Approaches in Hepatocellular Cancer Clinical Trials with Emerging Therapies Imaging is transforming HCC clinical trials, playing a pivotal role in diagnosis and monitoring treatment efficacy. Advanced techniques like triphasic CT and MRI are now essential for accurate tumor assessment, allowing for better differentiation of liver tumors and detection of subtle changes in arterial enhancement or necrosis. Additionally, the modified RECIST (mRECIST) criteria provides a more precise evaluation of tumor response, particularly for therapies targeting HCC’s complex tumor microenvironment. This is especially valuable across all trial phases, from early exploratory studies to late-phase registration trials. At Imaging Endpoints, we specialize in optimizing imaging charters for HCC trials, ensuring high-quality data and robust assessments that enhance trial outcomes. 🔗 Learn more about how our tailored imaging solutions can drive success in your HCC clinical trials: https://hubs.li/Q02WYj9g0 #HCC #ClinicalTrials #MedicalImaging #OncologyResearch #Pharma #ImagingEndPoints

1️⃣ Objective: To assess GPT-4's capability in answering clinically relevant questions based on ASCO and ESMO guidelines. 2️⃣ Method: GPT-4 responses were evaluated with and without retrieval-augmented generation (RAG). GPT-4 with RAG showed significantly higher accuracy. 3️⃣ Findings: GPT-4 with RAG provided 84% correct responses, whereas GPT-4 without RAG provided only 57% correct responses. 4️⃣ Guideline Comparisons: Key differences in recommendations for pancreatic, colorectal, and hepatocellular cancers were identified. For instance, ESMO uniquely proposed liver transplantation for certain colorectal cancer cases, and ASCO discussed socioeconomic factors affecting patient outcomes. 5️⃣ Performance Metrics: The study used faithfulness and relevance metrics for automated evaluation, supplemented by manual reviews from oncology experts. 6️⃣ Error Analysis: Among the incorrect responses, 4 were considered medically relevant due to factual misinformation, highlighting areas for model improvement.

The landscape of oncology is rapidly evolving with the advent of precision medicine. The FDA has sanctioned both gene- and immune-targeted medications for tissue-agnostic, genomic biomarker–driven indications in patients grappling with refractory solid tumors and hematologic malignancies. As the comprehension of the underlying science governing these cancers progresses, the roster of drugs authorized for tumors with genomic aberrations is expected to burgeon. Delve deeper into tissue-agnostic targeted therapies to unearth innovative treatments tailored to an individual's cancer, predicated on the specific genetic anomalies present in their tumor. Follow InviMeds Health to stay informed on the latest advancements and unique therapies tailored to individual genetic abnormalities, revolutionizing cancer care. #PrecisionMedicine #OncologyInnovation #TissueAgnosticTherapies #GenomicBiomarkers #CancerTreatment #InviMedsHealth #PersonalizedMedicine #PrecisionOncology #GeneticAbnormalities #ClinicalAdvancements #InviMedsHealth

We were thrilled today to present at the American Society of Clinical Oncology (ASCO) Annual Meeting. Two poster presentations spotlighted clinical trial data for Black Diamond’s #EGFR inhibitor BDTX-1535 in patients with recurrent #glioblastoma (GBM). These data were from a Phase 1 dose-escalation trial and a “window of opportunity” (Phase 0/1 “Trigger”) Investigator Sponsored Trial at the Ivy Brain Tumor Center.   Results demonstrated a favorable safety and tolerability profile and encouraging anti-tumor activity and duration of treatment. BDTX-1535 was also shown to achieve clinically meaningful drug levels in brain tumor tissue. Read more: https://lnkd.in/epsPKu_c View the posters here: https://lnkd.in/e3JeikQf   #ASCO2024 #GBM #oncology #biotech #healthcare #innovation

🚨 Don't miss out on Champions' industry-leading Systemic B-ALL In Vivo Screen! 🚨 Enroll your therapeutics by July 16th to advance your B-ALL cancer therapeutics with our clinically relevant hematological model cohort. Our fully characterized B-ALL PDX models, derived from primary patient samples, retain key clinical and molecular characteristics, ensuring the most accurate and insightful research outcomes. Don't miss this opportunity to advance your B-ALL research; enroll today: https://hubs.li/Q02DBBp40 #B-ALL #CancerResearch #Hematology #translationallResearch #Therapeutics #Bloodcancer #bloodmalignancies #BCellAcuteLymphoblasticLeukemia #cancertherapy #drugscreening